The perception of the Instituto de Medicina Tropical “Alexander von Humboldt” The integration of epidemiological, clinical and laboratory research is a.

Slides:



Advertisements
Similar presentations
Setting up a Molecular Lab in a Developing Country
Advertisements

CDCs 21 Goals. CDC Strategic Imperatives 1. Health impact focus: Align CDCs people, strategies, goals, investments & performance to maximize our impact.
DGIS -ITG IMT A. von HUMBOLDT (IMTAvH) Lima, Peru Institutional strengthening & collaboration.
BIOETHICS: THE SUBJECT, PURPOSE AND OBJECTIVES OF THE HEALTH CARE SYSTEM. BIOETHICS OF BIOMEDICAL EXPERIMENTS. INTERNATIONAL DOCUMENTS ON BIOETHICS AND.
MIcro-NanOSystems ECAD Laboratory GOSPEL : General Olfaction and Sensing Projects on a European Level Projects on a European Level A Network.
Advocacy for TB POC Diagnostic Javid Syed TB/HIV 15th Core Group Meeting Nov 3-4, Geneva.
BIRAX Regenerative Medicine Initiative Created by the British Embassy, Israel and the British Council with the aim of strengthening academic.
1 Core Module Three – The Summative Report Core Module Three: The Role of Professional Dialogue and Collaboration in the Summative Report.
Medical Diagnostics NIAID Funding Opportunities Maria Y. Giovanni, Ph.D. Assistant Director for Microbial Genomics and Advanced Technologies National Institute.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Bindley Bioscience Center Vision: Nurture interactive communication and interdisciplinary discovery with flexible laboratory project spaces and an open.
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Biomedical Research Networking Center Consortium (CIBER) Opportunities of collaboration with CIBERSAM R&D&I collaborations  Innovation in drugs  Innovation.
Presented by Dr. Jorge Arévalo Zelada Laboratorio de Biología Molecular y Celular de Tripanosomátidos IMTAvH-UPCH.
Rare Diseases Working Group Luzern, 24 September 2010.
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Laboratory Training for Field Epidemiologists Strengthening Laboratory and Epidemiology Collaboration Introduction May 2007.
Service System for Management and Sharing of Scientific Data in Medicine Depei Liu, Ph.D. Chinese Academy of Medical Sciences.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
FORESIGHT STUDY Future Trends and Challenges in Pathogenomics JUDITH SIMON & SVEN POMPE PROGRAMME GROUP MUT.
Libyan-UK partnership on Infectious Diseases Control Professor Abdulhafid A. Abudher MBBch,DGO,FRCOG,MD,FABOG Director of National Centre for Infectious.
European Health Forum Gastein, Bad Hofgastein, Austria, September 2002 Towards the Sixth Framework Programme Parallel Forum V 26 September 2002 Public.
Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.
Inter-sectoral coordination and social mobilization IDSP training module for state and district surveillance officers Module 12.
Responsible Conduct of Research (RCR) Farida Lada October 16, 2013
Institutional Evaluation of medical faculties Prof. A. Сheminat Arkhangelsk 2012.
Perspectives on the Sharing of Research Materials and Data Reid Adler Founder and Principal, Practical Innovation Strategy Washington, DC Presentation.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Syrian Arab Republic Ministry of Education Project of Integrating Technology in Education
1 SMEs – a priority for FP6 Barend Verachtert DG Research Unit B3 - Research and SMEs.
SECRETARÍA DE ESTADO DE UNIVERSIDADES E INVESTIGACIÓN Dirección General de Investigación 1 MINISTERIO DE EDUCACIÓN Y CIENCIA The Spanish National Programmes,
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.
Graduate studies - Master of Pharmacy (MPharm) 1 st and 2 nd cycle integrated, 5 yrs, 10 semesters, 300 ECTS-credits 1 Integrated master's degrees qualifications.
LEVELS OF HEALTH CARE VINITA VANDANA.
21/4/2008 Evaluation of control measures 1. 21/4/2008 Evaluation of control measures 2 Family and Community Medicine Department.
Other Intramural Training Opportunities at NCI Scientific DisciplinesProgram Population-based research, environmental & genetic determinants of cancer.
Susan R. Kayar, PhD Health Scientist Administrator Research Infrastructure NCRR, NIH Funding Opportunities through the National Center for Research Resources.
Iván Best 1, Angela Privat 1, Patricia Reyes 1, Francesca Falconi 1, María Cruz 2, Jean-Loup Lemesre 3, Jorge Arévalo 1, RAPSODI consortium 1 Institute.
While most HMORN projects involve two to five Network sites, its largest consortiums are the most widely recognized. Nearly 40% of HMORN projects and consortium.
Public Population Projects in Genomics International Working Groups Working Meeting September th, 2005, Hinxton, UK.
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
Consultant Advance Research Team. Outline UNDERSTANDING M&E DATA NEEDS PEOPLE, PARTNERSHIP AND PLANNING 1.Organizational structures with HIV M&E functions.
Robert H. Wiltrout Director, CCR Director’s Address.
NIH and the Clinical Research Enterprise Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institute of Health.
Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority? November 2009, dar Es Salaam.
Mt. Hood. IOM Report: 10 Years After & More Coming Mitch Greenlick, Ph.D. Oregon State Representative April 21, 2010.
Summary of potential priority actions for CMWG Case Management Working Group Meeting 8-9 July 2009.
Correspondence: Bustamante, B: Campos PE: Denning DW:
NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.
Research networks in movement disorders Joaquim Ferreira, MD, PhD Instituto de Medicina Molecular Faculdade de Medicina de Lisboa.
 The Work of Civil Society in the Field of HIV Prevention Brussels, 23 February 2011 The Work of European AIDS Treatment Group (EATG) 1.
GCP (GOOD CLINICAL PRACTISE)
REDESIGNING ORGANIZATION & MANAGEMENT SYSTEMS (IHSDNs Attributes # 7, 8, 9,10, 11, 12, 13) (IHSDNs Attributes # 7, 8, 9,10, 11, 12, 13) July , 2015.
A Productive Partnership
laboratory management
Semantic Web - caBIG Abstract: 21st century biomedical research is driven by massive amounts of data: automated technologies generate hundreds of.
Outbreak Investigations
REGULAR EVALUATION OF ESTONIAN RESEARCH AND DEVELOPMENT
Patients w/AIDS-defining illness
Lecture 9: PHC As a Strategy For HP Dr J. Sitali
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Research Integrity & RMIT
A new approach to delivery
MAX IV Laboratory National Synchrotron Light Source – two storage rings (1.5 & 3.0 GeV) and a Short Pulse Facility Characteristics of User Program: 15.
PrEParedness for the Rollout of Effective HIV Prevention among Key Affected Populations in Brazil, Peru, and Mexico The Imprep pROJECT Valdiléa G. Veloso,
Clinical and Translational Science Awards Program
11 iii. Define management and supervision roles and responsibilities
The FaceBase Consortium
M-H Pinard-van der Laan
Presentation transcript:

The perception of the Instituto de Medicina Tropical “Alexander von Humboldt” The integration of epidemiological, clinical and laboratory research is a requisite for the comprehensive understanding of the disease phenomenon.

-1- DGIS Major Goal Institutional strengthening of the Instituto de Medicina Tropical “Alexander von Humboldt” (IMTAvH) of the Universidad Peruana Cayetano Heredia through the improvement of human resources and research capabilities to work on endemic diseases that are major public health problems.

Chosen Strategy The DGIS project has evolved using a flexible framework that adapted the material resources to the needs of each component. Such flexibility allowed to tailor the training platforms and to refine the scientific progress according to maturation of each component. The following aspects were followed:

 To conduct specific collaborative research projects between partners of the IMTAvH and the Prince Leopold Institute of Tropical Medicine (IMT). The targeted health problems were: leishmaniasis, malnutrition, mycosis and tuberculosis. These projects involve the participation of young Peruvian scientists who later on might be incorporated into the IMTAvH research staff.

 To build up an intramural multidisciplinary research team at the IMTAvH, with the capability to study relevant infectious diseases using diverse and complementary approaches.  To create physical core facilities to carry out molecular biology procedures and for the cryobanking of valuable biomedical material

DGIS antecedents and evolution A general Agreement was signed by the IMTAvH and the IMT in the mid 80´s (H. Guerra and Luc Eyckmans). In 1988 started a collaborative research between the Molecular and Cellular Biology of Trypanosomatids from the IMTAvH and the Protozoology group from the IMT. This is one of the more long lasting and fruitful collaborations between Belgian and Peruvian partners that it is still ongoing.

In 1990 Jean Claude Dujardin came to the IMTAvH to pursue part of his PhD studies. In 1998 Kathleen Victoir came for the same purpose. In 1996 the inter institutional agreement was renewed (E. Gotuzzo and B. Gryseels).

In 1998 started current project when a contract was signed within the DGIC/ ITMA Framework Agreement. At the beginning it comprised four different fields: Parasitology, Nutrition, Mycology and Bacteriology. A new component, the Clinical one, was incorporated in year 2000.

Research Topics and their Leaders  Clinical epidemiology and clinical trials (E. Gotuzzo, B. Gryseels, T. Verdonck)  Malnutrition and micronutrient deficiencies (I. Pecho, Ana Prada, P. Kolsteren)  Mycoses (B. Bustamante, D. Swinne)  Tegumentary leishmaniasis (J. Arevalo, J.C. Dujardin, D. Le Ray)  Tuberculosis and Buruli ulcer (H. Guerra, F. Portaels)

Remarkable aspects of each component  Clinical epidemiology and clinical trials: its agglutination role on the other components devoted to infectious agents; the onset of HIV co-infection studies; the translation into Spanish of the CDRom on tropical diseases, edited by IMT.

 Malnutrition and micronutrient deficiencies: working with the communities to set up the basis for subsequent studies; the onset of relationship between malnutrition and infectious diseases.

 Mycoses: the incorporation of molecular tools for characterization of fungi, the upgrade of research conditions that will allow blending of conventional and robust mycology with the modern molecular biology approach.

 Tegumentary leishmaniasis: transfer of molecular biology methods to other components; detection and characterization of Leishmania without the need of culture but using molecular tools; onset of gene expression studies to study pathogen virulence factors; to set up an animal model to study the effect of Vitamin A on disease progression.

 Tuberculosis and Buruli ulcer: safety laboratory upgrade to work with drug resistant M. tuberculosis strains; adaptation of drug resistant diagnostic procedures; the onset of molecular characterization studies here in Lima (2002).

These were major instruments for DGIS project progress. They occur at three different levels: Working Travels

 Coordination meetings at both institutional and specific component levels.  Short visits for technological transfer from the IMT to the IMTAvH or for learning specific skills at the IMT.  Long training periods within a post graduate program aimed to achieve a title.

Common Activities and Core Facilities Natural project evolution: from the vertical approach to the horizontal networking. Two major products can be identified in terms of synergic integration. Following temporal order:

 Laboratory – Laboratory: Technological transfer of molecular characterization tools to Mycology and Mycobacterium units  Clinical – Laboratory: Skin ulcer and TBC clinical studies

Two major products can be identified in terms of research power up grade:  PCR room  Cryobanking room

It will permit to use common equipment like thermocyclers, electrophoresis apparatus, image recording and to carry out amplicons manipulation under good practice rules to avoid DNA contamination and achieve reliable data acquisition. This is crucial when you work with patient sample material that is very difficult to collect and almost always there is no possibility to obtain a second sample from him/her. PCR room

Cryobanking room  To storage valuable biomedical sample material for intra and extra mural research groups, keeping the higher cryobanking standards.  A strategic instrument for leverage inter institutional collaboration.

 The first step towards a Biological Resource Center in collaboration with the BCCM/IHEM fungal collection of the Scientific Institute of Public Health, Brussels-Belgium. This will mean to carry out activities to incorporate intellectual and proprietary rights aspects.

Next Step Towards research for the comprehensive understanding of the Reality, where disease is a manifestation of environment- pathogen-host interactions EPIDEMIOLOGY – Clinics - Laboratory

DGIS Funding

Percentage of BEF/year devoted to Lima and Antwerp

Final Percentage Received by IMTAvH and ITMA ( )

Funding Percentage in Lima ( )

Funding Percentage in Antwerp ( )

Full Percentage Distribution According Components ( )

BEF for each Component per year